Skip to main content
SpringerLink
Log in

Leishmaniasis Vaccine

  • Section 2: Prophylactic Anti-Infective Vaccines
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Convit J, Rondon A, Ulrich M, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987 Feb 21; 1: 401–4

    Article  PubMed  CAS  Google Scholar 

  2. Armijos RX, Weigel MM, Aviles H, et al. Field trial of a vaccine against new world cutaneous leishmanias in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998 May; 177: 1352–7

    Article  PubMed  CAS  Google Scholar 

  3. Xu D, McSorley SJ, Chatfield SN, et al. Protection against Leishmania major infection in genetically susceptible BALB/c mice by GP63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-). Immunology 1995 May; 85: 1–7

    PubMed  CAS  Google Scholar 

  4. Lezama-Dávila CM, Gallagher G. Vaccination of C57BL/6 mice against cutaneous leishmaniosis. Kinetics of antibody synthesis and induction of cellular responses. In Vivo 1995 Sep–Oct; 9: 519–24

    PubMed  Google Scholar 

  5. Frankenburg S, Axelrod O, Kutner S, et al. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine 1996 Jun; 14: 923–9

    Article  PubMed  CAS  Google Scholar 

  6. Connell ND, Medina-Acosta E, McMaster WR, et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci U S A 1993 Dec 15; 90: 11473–7

    Article  PubMed  CAS  Google Scholar 

  7. Afonso LCC, Scharton TM, Vieira LQ, et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994 Jan 14; 263: 235–7

    Article  PubMed  CAS  Google Scholar 

  8. Nascimento E, Mayrink W, Dacosta CA, et al. Vaccination of humans against Cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 1990 Jul; 58: 2198–203

    PubMed  CAS  Google Scholar 

  9. Mendonca SCF, De Luca PM, Mayrink W, et al. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 1995 Aug; 53: 195–201

    PubMed  CAS  Google Scholar 

  10. Playfair JHL, Blackwell JM, Miller HRP. Parasitic diseases. Lancet 1990 May 26; 335: 1263–6

    Article  PubMed  CAS  Google Scholar 

  11. Sharifi I, FeKri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998 May 23; 351: 1540–3

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leishmaniasis Vaccine. Drugs R&D 2, 208–210 (1999). https://doi.org/10.2165/00126839-199902030-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902030-00014

Keywords

Search

Navigation